悉尼科学家Georgina Long因领导开发个性化mRNA癌症疫苗研究而获得澳大利亚顶级科学奖Eureka Prize1。该疫苗由Moderna和Merck共同开发，旨在预防黑色素瘤手术切除后的复发1。第三阶段临床试验纳入1137名高危黑色素瘤患者，其中一半患者接受实验性疫苗联合免疫疗法Keytruda，另一半仅接受Keytruda1。2024年6月公布的第二阶段试验结果显示，联合治疗使复发或死亡风险降低49%1。
Long的研究工作取得突破性进展，将晚期黑色素瘤的生存率从5%提升至50%1。根据2018年的试验数据，联合两种免疫疗法（nivolumab和ipilimumab）的患者反应率达到46%，7年随访显示51%的患者得以存活1。该治疗策略的成功也被应用于肺癌、肾癌等其他多种癌症类型1。Moderna在8月20日宣布试验取得成功后，其市值单日跃升620亿美元1。完整的试验结果将于2024年10月发布1。Long和同事Richard Scolyer因其癌症研究贡献，于2024年获得澳大利亚年度人物称号1。
Georgina Long, a researcher based in Sydney, has been awarded the Eureka Prize, Australia's premier science award, for her leadership in developing a personalized mRNA cancer vaccine 1. The vaccine, created through collaboration between Moderna and Merck, is designed to prevent recurrence of melanoma following surgical removal 1.
Clinical trial results have demonstrated significant therapeutic advances in melanoma treatment. A phase three trial involving 1,137 high-risk melanoma patients compared combined treatment—the experimental vaccine plus Keytruda—against Keytruda alone 1. Results announced in June 2024 showed that the combined approach reduced the risk of recurrence or death by 49% 1. Long's research has raised the survival rate for advanced melanoma patients from 5% to 50% 1.
The vaccine development builds on earlier findings from a 2018 trial examining the combination of two immunotherapies, nivolumab and ipilimumab, which achieved a 46% response rate with 51% of patients surviving at seven-year follow-up 1. Long's pioneering treatment strategy has been extended to other cancers including lung and kidney cancers 1. Moderna announced the trial's success on August 20, triggering a single-day market value increase of 62 billion dollars 1. Complete trial results are scheduled for release in October 2024 1. Long and her colleague Richard Scolyer were jointly recognized as Australian of the Year in 2024 for their cancer research contributions 1.
评论
还没有评论，欢迎留下第一条。